ANEW Medical, Inc. Shares Soar 147% Premarket on Key European Patent Win

ANEW Medical, Inc. (NASDAQ: WENA) a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders, experienced a 147% surge in premarket shares. The spike followed the announcement of a new European patent for its secreted Klotho gene therapy aimed at treating cognitive decline and neurodegenerative diseases. 

Highlights:

  • Strategic Intellectual Property: ANEW Medical, Inc. has secured a crucial patent, EP3377091B1, in Europe for its innovative human Klotho gene RNA splice variant and protein technology. This patent represents a significant step forward in in the company’s global expansion strategy, enhancing its efforts to combat neurological and age-related disorders.
  • Exclusive Licensing Agreement: The company holds an exclusive, worldwide license for this technology, originally developed by researchers at Universitat Autònoma de Barcelona (UAB) and Institució Catalana de Recerca i Estudis Avançats (ICREA).
  • Global Expansion and Development: With this patent, ANEW plans to broaden its intellectual property portfolio and initiate product development across Asian markets starting in 2024. The technology is already patented in China and Hong Kong, setting the stage for a comprehensive Asian market entry.
  • Groundbreaking Therapeutic Potential: According to Dr. Joseph Sinkule, CEO of ANEW Medical, the patented technology will play a crucial role in developing therapies for diseases like Alzheimer’s, Parkinson’s, Huntington’s, and ALS. The secreted Klotho RNA splice variant, known as s-KL, is pivotal in brain function and could revolutionize treatment approaches for these debilitating conditions.
  • Future Medical Applications: ANEW is not only focusing on neurodegenerative diseases but also exploring the use of s-KL in other medical therapies. This includes potential developments in gene therapy and interaction studies with other significant proteins and genes, enhancing the company’s portfolio in treatment options.

Read the full release HERE

ANEW Medical began trading on the NASDAQ Global Market on Monday, June 24th.

About ANEW MEDICAL, INC.: 
ANEW MEDICAL is a biopharmaceutical company specializing in the advancement of novel disease-modifying therapies for neurological and age-related disorders. The company’s focus on central nervous systems (CNS) diseases utilizing cell and gene therapies to mitigate age-related pathologies such as Alzheimer’s disease, dementia symptoms and neuromuscular diseases. The Company has exclusive worldwide rights to develop and commercialize proprietary product platforms based on its proprietary isoform transcribed from the human Klotho gene referred to as secreted Klotho or “s-KL”. This s-KL protein or gene therapy has been recognized for its potential to mitigate age-related pathologies such as ALS, Alzheimer’s and Parkinson’s Disease. The Company is also evaluating other core technology platforms to acquire for development and commercialization by the Company. For more information, please visit: www.anewmeds.com.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

ANEW Medical, Inc. Shares Soar 147% Premarket on Key European Patent Win

Ashlee Vogenthaler

Markets Editor